Jane Hvarregaard Christensen

Jane Hvarregaard Christensen

Auto-generated profile, based on publicly available information

Jane Hvarregaard Christensen

Department of Biomedicine Aarhus University Aarhus Denmark

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2019 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JGJakob Grove
Jakob Grove
SRStephan Ripke
Stephan Ripke
TAThomas D. Als
Thomas D. Als
MMManuel Mattheisen
Manuel Mattheisen
RWRaymond K. Walters
Raymond K. Walters
BUBupgen
Bupgen
Autism spectrum disorder (ASD) is a highly heritable and heterogeneous group of neurodevelopmental phenotypes diagnosed in more than 1% of children. Common genetic variants contribute substantially to ASD susceptibility, but to date no individual variants have been robustly associated with ASD. With a marked sample-size increase from a unique Danish population resource, we report a genome-wide association meta-analysis of 18,381 individuals with ASD and 27,969 controls that identified five genome-wide-significant loci. Leveraging GWAS results from three phenotypes with significantly overlapping genetic architectures (schizophrenia, major depression, and educational attainment), we identified seven additional loci shared with other traits at equally strict significance levels. Dissecting the polygenic architecture, we found both quantitative and qualitative polygenic heterogeneity across ASD subtypes. These results highlight biological insights, particularly relating to neuronal function and corticogenesis, and establish that GWAS performed at scale will be much more productive in the near term in ASD.

25 July 2015 in BMC Genomics
Verified
Journal Article
Open access
PDF file
ARAnto P. Rajkumar
Anto P. Rajkumar
PQPer Qvist
Per Qvist
RLRoss Lazarus
Ross Lazarus
FLFrancesco Lescai
Francesco Lescai
JJJia Ju
Jia Ju
JCJane H. Christensen
Jane H. Christensen
Massively parallel cDNA sequencing (RNA-seq) experiments are gradually superseding microarrays in quantitative gene expression profiling. However, many biologists are uncertain about the choice of differentially expressed gene (DEG) analysis methods and the validity of cost-saving sample pooling strategies for their RNA-seq experiments. Hence, we performed experimental validation of DEGs identified by Cuffdiff2, edgeR, DESeq2 and Two-stage Poisson Model (TSPM) in a RNA-seq experiment involving mice amygdalae micro-punches, using high-throughput qPCR on independent biological replicate samples. Moreover, we sequenced RNA-pools and compared their results with sequencing corresponding individual RNA samples. False-positivity rate of Cuffdiff2 and false-negativity rates of DESeq2 and TSPM were high. Among the four investigated DEG analysis methods, sensitivity and specificity of edgeR was relatively high. We documented the pooling bias and that the DEGs identified in pooled samples suffered low positive predictive values. Our results highlighted the need for combined use of more sensitive DEG analysis methods and high-throughput validation of identified DEGs in future RNA-seq experiments. They indicated limited utility of sample pooling strategies for RNA-seq in similar setups and supported increasing the number of biological replicate samples.

17 June 2019 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
DDDitte Demontis
Ditte Demontis
VRVeera Manikandan Rajagopal
Veera Manikandan Rajagopal
TTThorgeir E. Thorgeirsson
Thorgeir E. Thorgeirsson
TAThomas D. Als
Thomas D. Als
JGJakob Grove
Jakob Grove
ABAnders D. Børglum
Anders D. Børglum

1 March 2021 in The Lancet Child & Adolescent Health
Verified
Journal Article
Closed access
CJCecilie S Jørgensen
Cecilie S Jørgensen
HHHenriette T Horsdal
Henriette T Horsdal
VRVeera M Rajagopal
Veera M Rajagopal
JGJakob Grove
Jakob Grove
TAThomas D Als
Thomas D Als
JCJane H Christensen
Jane H Christensen

31 October 2012 in British Journal of Nutrition
Verified
Journal Article
Open access
PDF file
JAJulie Aarestrup
Julie Aarestrup
CKCecilie Kyrø
Cecilie Kyrø
KKKnud Erik Bach Knudsen
Knud Erik Bach Knudsen
EWElisabete Weiderpass
Elisabete Weiderpass
JCJane Christensen
Jane Christensen
AOAnja Olsen
Anja Olsen
The phyto-oestrogen enterolactone has been hypothesised to protect against hormone-dependent cancers, probably through its anti-oestrogenic potential. We investigated whether a higher level of plasma enterolactone was associated with a lower incidence of endometrial cancer in a case–cohort study in the ‘Diet, Cancer and Health’ cohort. The cohort study included 29 875 women aged 50–64 years enrolled between 1993 and 1997. Information on diet and lifestyle was provided by self-administrated questionnaires and blood was drawn from each participant. Time-resolved fluoroimmunoassay was used for biochemical determination of plasma enterolactone. A total of 173 cases and 149 randomly selected cohort members were included. We estimated incidence rate ratio (IRR) and 95 % CI by a Cox proportional hazards model. A 20 nmol/l higher plasma concentration of enterolactone was associated with a non-significant lower risk of endometrial cancer (IRR 0·93, 95 % CI 0·84, 1·04). When excluding women with low enterolactone concentrations (quartile 1) due to potential recent antibiotic use, the association became slightly stronger, but remained non-significant (IRR 0·90, 95 % CI 0·79, 1·02). Menopausal status, hormone replacement therapy or BMI did not modify the association. In conclusion, we found some support for a possible inverse association between plasma enterolactone concentration and endometrial cancer incidence.

12 January 2022 in Acta Oncologica
Verified
Journal Article
Open access
CSCharlotte Wessel Skovlund
Charlotte Wessel Skovlund
SFSøren Friis
Søren Friis
JCJane Christensen
Jane Christensen
MNMef Nilbert
Mef Nilbert
LMLina Steinrud Mørch
Lina Steinrud Mørch
Several countries have reported a decline in cancer diagnoses during the COVID-19 pandemic [1–7]. The European Cancer Organisation estimated that clinicians diagnosed 1.5 million fewer cancer patie...